Here are the 424B prospectus supplements from DarioHealth Corp. (DRIO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow DRIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DRIO filings page.
DarioHealth Corp. is conducting a registered direct offering under its shelf registration, issuing 2,451,490 shares of common stock and pre-funded warrants to purchase 1,017,499 shares. Common stock is priced at $6.80 per share (with 14,430 shares purchased by a director at $6.93), and the pre-funded warrants are priced at $6.7999 with a de minimis exercise price of $0.0001 per share and no expiration date.
The total offering amount is $23,590,899, with placement agent fees of $482,808 and $23,108,091 in proceeds to the company before expenses; DarioHealth estimates net proceeds of approximately $23.6 million for working capital, investments, acquisitions, and general corporate purposes. The deal is on a “reasonable best efforts” basis with no minimum offering amount, so fewer securities may be sold.
The company reports a going concern uncertainty: as of March 31, 2026 it had $20.0 million in cash, cash equivalents and short-term bank deposits versus $9.4 million in current liabilities and does not believe existing cash will fund planned operations for 12 months without additional capital. The pre-funded warrants include beneficial ownership limits of 4.99% (or 9.99% at holder election) and will not be listed, limiting their liquidity.
DarioHealth Corp. intends to offer and sell shares of its common stock in an at-the-market offering of up to $20,000,000 of aggregate gross proceeds through A.G.P./Alliance Global Partners as sales agent.
The prospectus supplement states shares may be sold from time to time on Nasdaq or in other market transactions, the Agent may act as agent or principal, and the Agent’s commission may be up to 3.0% of gross sales. The number of shares to be issued will vary with market prices; the prospectus illustration assumes sales at the last reported sale price of $8.11 per share on March 27, 2026.